By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



4921 Birch Street
Suite 120
Newport Beach  California  92660  U.S.A.
Phone: n/a Fax: 949-266-5572


Bonti is a rapidly emerging biotech company focused on developing novel treatments, driven by our unique neurotoxin platform, for aesthetic and therapeutic indications for conditions with unmet needs.


June 13, 2015


Co-Founder & CEO: Fauad Hasan, MS, MBA

Co-Founder & COO: Wajdie Ahmad, MBA

Co-Founder & Executive VP, Drug Development: Mike Jarpe, Ph.D.

Co-Founder & Director: David Ramsay

Director: Dennis Huang

Director: Tom Albright


Please click here for Bonti's job opportunities.

Key Statistics

Ownership: Private

Web Site: Bonti


Company News
Bonti Announces Presentation Of EB-001 Clinical Study Results At American Society for Dermatologic Surgery Annual Meeting 9/13/2017 8:28:50 AM
Bonti Announces Start Of LANTERN-1 Phase II Clinical Study Evaluating EB-001 In Reducing Musculoskeletal Pain 8/23/2017 7:55:04 AM
Bonti Announces Topline Results Of EB-001 Phase IIA Clinical Study In Glabellar Lines 8/10/2017 6:37:34 AM
Bonti Announces Poster Presentation On EB-001 Pharmacological Profile At Abdominal Wall Reconstruction Conference 6/6/2017 9:32:23 AM
Bonti Announces Hot Topics Presentation Of Phase IIa Interim Clinical Data At The Aesthetic Meeting 2017 5/3/2017 9:07:17 AM
Bonti Announces Inaugural Presentation Of Phase IIa Clinical Data For Its Lead Product EB-001 4/27/2017 9:20:03 AM
Bonti Raises $11.7 Million In An Oversubscribed Series B Financing To Advance Development Of Lead Product EB-001 4/18/2017 11:25:50 AM